
Clinical observation of galantamine hydrobromide combined with mannitol sodium in the treatment of cognitive impairment after stroke
Pida HAO, Yang WANG, Ran SU, Xiaojuan ZHAO, Kuanfei TANG, Yingke LIU, Yuling SHANG
Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2024, Vol. 7 ›› Issue (2) : 110-113.
Abbreviation (ISO4): Chinese Journal of Alzheimer's Disease and Related Disorders
Editor in chief: Jun WANG
Clinical observation of galantamine hydrobromide combined with mannitol sodium in the treatment of cognitive impairment after stroke
Objective: To investigate the clinical efficacy of galantamine hydrobromide combined with manamide sodium in the treatment of cognitive impairment after stroke. Methods: 130 stroke patients admitted to our hospital from June 2022 to December 2023, all with cognitive dysfunction, were divided into the combined group and the galantamine group according to envelope method; patients in the galantamine hydrobromide group were treated with galantamine hydrobromide; patients in the combined group were treated with manamide sodium combined treatment. The clinical efficacy of the two groups was compared. Neurological and cognitive function scores, serum HCY and NSE levels were compared between the two groups before and after treatment to observe the occurrence of adverse reactions. Results: Compared with galantamine hydrobromide group, the combined group had lower CSS score and higher MMSE score after treatment (P<0.05). Compared with galantamine hydrobromide group (86.15%), the therapeutic effect of combined group (95.38%) was significantly higher (χ2=10.883, P=0.004). After treatment, the levels of HCY and NSE in combination group were significantly lower than those in galantamine hydrobromide group (P<0.05). The incidence of adverse reactions in combination group (4.17%) was significantly lower than that in galantamine group (16.92%) (χ2=5.123, P=0.024). Conclusion: Galantamine hydrobromide combined with manamide sodium has significant clinical efficacy in the treatment of cognitive impairment after stroke, which can significantly improve the neurological function and cognitive function of patients, improve serological indexes, and alleviate adverse reactions, and is worthy of further clinical promotion.
Galantamine hydrobromide / Sodium manamide / Cognitive impairment after stroke / Cognitive function
[1] |
|
[2] |
许济, 李花, 田苗, 等. 脑卒中后认知功能障碍发生率及其危险因素分析[J]. 安徽医药, 2021, 25(2):321-325.
|
[3] |
汪凯, 董强, 郁金泰, 等. 卒中后认知障碍管理专家共识2021[J]. 中国卒中杂志, 2021, 16(4):376-389.
|
[4] |
|
[5] |
吴孟娇, 王景信, 邵芃, 等. 甘露特钠胶囊治疗卒中后认知障碍的临床疗效分析[J]. 航空航天医学杂志, 2023.
|
[6] |
金庆文, 王颖. 氢溴酸加兰他敏胶囊改善老年及老年前期者记忆障碍的临床观察[J]. 脑与神经疾病杂志, 2024, 1(3):165-167.
|
[7] |
Cognitive impairment and dementia are highly prevalent among stroke survivors and represent a major burden for patients, carers, and health-care systems. We studied the risk factors for post-stroke cognitive impairment (PSCI) and dementia (PSD) beyond the well established risk factors of age and stroke severity.In this systematic review and meta-analysis we conducted a systematic literature search from database inception until Sept 15, 2023. We selected prospective and retrospective cohort studies, post-hoc analyses from randomised controlled trials, and nested case-control studies of patients with acute stroke (ischaemic, haemorrhagic, and transient ischaemic attack), exploring associations between risk factors at baseline and PSCI or PSD over a follow-up period of at least 3 months. Study quality was assessed using the Newcastle-Ottawa quality assessment scale. We calculated pooled relative risks (RRs) with random-effects meta-analyses and performed subgroup, meta-regression, and sensitivity analyses. This study was preregistered with PROSPERO, CRD42020164959.We identified 162 eligible articles for our systematic review, of which 113 articles (89 studies, 160 783 patients) were eligible for meta-analysis. Baseline cognitive impairment was the strongest risk factor for PSCI (RR 2·00, 95% CI 1·66-2·40) and PSD (3·10, 2·77-3·47). We identified diabetes (1·29, 1·14-1·45), presence or history of atrial fibrillation (1·29, 1·04-1·60), presence of moderate or severe white matter hyperintensities (WMH; 1·51, 1·20-1·91), and WMH severity (1·30, 1·10-1·55, per SD increase) as treatable risk factors for PSCI, independent of age and stroke severity. For PSD, we identified diabetes (1·38, 1·10-1·72), presence of moderate or severe WMH (1·55, 1·01-2·38), and WMH severity (1·61, 1·20-2·14, per SD increase) as treatable risk factors. Additional risk factors included lower educational attainment, previous stroke, left hemisphere stroke, presence of three or more lacunes, brain atrophy, and low baseline functional status. Associations of risk factors with PSD were weaker in studies conducted and published more recently. We found substantial interstudy heterogeneity and evidence of reporting bias.Our results highlight the importance of cognitive impairment in the acute phase after stroke for long-term prediction of PSCI and PSD. Treatable risk factors include diabetes, atrial fibrillation, and markers of cerebral small vessel disease (ie, white matter hyperintensities and lacunes). Future trials should explore these risk factors as potential targets for prevention of PSCI and PSD.German Research Foundation.Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
|
[8] |
|
[9] |
金庆文, 王颖. 氢溴酸加兰他敏胶囊改善老年及老年前期者记忆障碍的临床观察[J]. 脑与神经疾病杂志, 2024, 1997(3):165-167.
|
[10] |
尤丰玲, 夏高富, 蔡静, 等. 甘露特钠治疗阿尔茨海默病源性轻度认知障碍合并甲状腺功能减退症-桥本氏甲状腺炎1例[J]. 国际老年医学杂志, 2023, 44(1):125-128.
|
[11] |
|
[12] |
汪峰, 杨楠, 彭慧渊, 等. 脑小血管病认知障碍特点及与影像学总负荷评分的关系[J]. 中国实用神经疾病杂志, 2021, 24(1):7-12.
|
[13] |
李冬梅. 经颅磁刺激联合药物治疗阿尔茨海默病改善患者认知功能、精神行为症状及神经递质的效果[J]. 中国临床医生杂志, 2023, 51(10):1183-1185.
|
[14] |
王特, 赵伟, 刘艳, 等. 阿尔茨海默病采用甘露特钠配合多奈派齐治疗的效果[J]. 慢性病学杂志, 2023, 24(9):1425-1427.
|
[15] |
宋冬晶, 刘斌, 钟莺, 等. 甘露特钠胶囊联合盐酸多奈哌齐片治疗痴呆患者的临床疗效及安全性[J]. 阿尔茨海默病及相关病, 2022, 5(4):295-299.
|
[16] |
|
[17] |
杨乐, 刘婷婷, 刘丹, 等. 多种血清标志物预测老年急性缺血性脑卒中患者卒中后认知障碍的研究[J]. 神经疾病与精神卫生, 2024, 24(2):83-88.
|
[18] |
吴孟娇, 王景信, 邵芃, 等. 甘露特钠胶囊治疗卒中后认知障碍的临床疗效分析[J]. 航空航天医学杂志, 2023, 34(6):654-657.
|
/
〈 |
|
〉 |